search

Active clinical trials for "Biliary Tract Neoplasms"

Results 211-220 of 325

Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary...

Biliary Tract Neoplasms

As a result of our previous NCRN study (ABC-02) cisplatin and gemcitabine (CisGem) is likely to become the international standard of care for patients with advanced biliary tract cancer (submitted: ASCO 2009). This study, ABC-03, will determine whether the addition of cediranib(an oral Vascular Endothelial Growth Factor Receptor inhibitor) to CisGem will improve the time to disease progression in this patient group.

Completed33 enrollment criteria

The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary...

Pancreatic NeoplasmsBiliary Tract Neoplasms

The purpose of this study is to assess the efficacy of combination therapy with gemcitabine and docetaxelin in patients with locally advanced or metastatic pancreatic or biliary adenocarcinoma.

Completed13 enrollment criteria

The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective...

Biliary Tract DiseasesGallbladder Cancer4 more

The aim of the study is to establishing a standardized biobank and a clinical information database for patients with benign and malignant tumors of the biliary system. With follow-up plans and advanced multiomics technology, a multiomics database for patients with benign and malignant tumors of the biliary tract will be further established. Based on the above work, real-world clinical research on the diagnosis and treatment of biliary tract tumors is about to be carried out, and a high-standard cohort research foundation is laid for precision therapy based on multiomics characteristics and molecular typing of biliary tract tumors.

Not yet recruiting10 enrollment criteria

TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer

Biliary Tract Neoplasms

TST001 is a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. This is an open-label, single-arm phase II study to evaluate the efficacy and safety of TST001 for patients with CLDN18.2 positive previously treated unresectable advanced or metastatic Biliary Tract Cancer.

Completed14 enrollment criteria

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With...

Advanced Solid TumorsColorectal Cancer2 more

This is a Phase 1/2, open-label, multicentric, non-randomised, parallel-arm study that aims to establish the safety, tolerability, and initial efficacy of CAN04 in combination with 3 SoC chemotherapies (mFOLFOX, DTX, and G/C).

Completed65 enrollment criteria

Trastuzumab in HER2-positive Biliary Tract Cancer

CholangiocarcinomaBiliary Tract Cancer2 more

Trastuzumab is approved for the treatment of HER2-positive breast cancer and gastric cancer. The recent study showed that HER2 overexpression or amplification is noted about 5-15% of total biliary tract cancer patients. The aim of this study is to evaluate the efficacy and safety of trastuzumab in the combination of current standard gemcitabine plus cisplatin.

Completed29 enrollment criteria

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

Heptocellular CancerBiliary Tract Neoplasms3 more

Background: - Tremelimumab is a cancer treatment drug that helps the immune system recognize and destroy cancer cells. Researchers want to see if it can be used to treat advanced liver cancer. The drug will be given with one of two types of treatment for liver cancer. The first type, transarterial catheter chemoembolization (TACE), injects chemotherapy drugs into the tumor through the main blood vessel that is feeding it. That blood vessel is then closed off to help keep the drugs in the tumor longer. The second type, radiofrequency ablation (RFA), uses a heated probe to destroy the tumor tissue. Researchers want to study how safe and effective these treatments are with the study drug. Objectives: - To test the safety and effectiveness of Tremelimumab with TACE or RFA for advanced liver cancer. Eligibility: - Individuals at least 18 years of age who have advanced liver cancer that has not responded to other treatments.

Completed36 enrollment criteria

X-MAS Biliary Study With Covered Biliary Stent

Biliary Tract Cancer

The purpose of this study is to provide safety and efficacy data for the X-Suit NIR® Covered Biliary Metallic Stent for subjects with malignant stricture(s) in the biliary tree. The study is designed to support the regulatory requirement of a 510(k) marketing application in the United States.

Completed14 enrollment criteria

Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary...

Biliary Tract CancerGallbladder Cancer2 more

The purpose of this study is to determine whether fit patients (with ECOG performance score of 0-1) with advanced biliary tract cancer (ABC) benefit from chemotherapy in the second-line setting (after prior therapy with cisplatin and gemcitabine) in terms of overall survival.

Completed22 enrollment criteria

Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents

Biliary Tract NeoplasmsJaundice1 more

Endoscopic retrograde biliary drainage (ERBD) is now widely accepted as the standard intervention for the relief of obstructive jaundice in patients with unresectable malignant biliary obstruction. Although plastic stents (PSs) were developed earlier, self-expandable metal stents (SEMSs) are now used widely as the initial choice for ERBD in this setting, as SEMSs offer longer patency.However, SEMSs do become occluded in some patients. There are a limited number of reports on the management of occluded SEMS with various results. The aim of this study is to compare the efficacy of ComVi stents SEMSs with uncovered SEMS in subsequent ERBD after the occlusion of initial SEMSs.

Completed15 enrollment criteria
1...212223...33

Need Help? Contact our team!


We'll reach out to this number within 24 hrs